

## Efficient synthesis of (±)- $\gamma$ -lycorane employing stereoselective conjugate addition to nitroolefin

Tomohisa Yasuhara,<sup>a</sup> Emi Osafune,<sup>a</sup> Katsumi Nishimura,<sup>b</sup> Mitsuaki Yamashita,<sup>b</sup>  
Ken-ichi Yamada,<sup>b</sup> Osamu Muraoka<sup>a</sup> and Kiyoshi Tomioka<sup>b,\*</sup>

<sup>a</sup>School of Pharmaceutical Sciences, Kinki University, 3-4-1 Kowakae, Higashi-osaka, Osaka 577-8502, Japan

<sup>b</sup>Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan

Received 3 February 2004; revised 17 February 2004; accepted 19 February 2004

**Abstract**—(±)- $\gamma$ -Lycorane **3** was synthesized in 52% overall yield via seven steps from **5** by employing the highly stereoselective nitro-Michael cyclization of **5** to **9** and diastereoselective conjugate addition of aryllithium to a nitroolefin **10** as two key steps.  
© 2004 Elsevier Ltd. All rights reserved.

We have been involved in the asymmetric synthesis of biologically active lycorine alkaloids **1–4**<sup>1,2</sup> through the conjugate addition to nitroolefin<sup>3,4</sup> and cyclization technology (Fig. 1). Deoxygenated skeletons of **4**,  $\alpha$ - and  $\beta$ -lycoranes **1** and **2**,<sup>5,6</sup> were successfully synthesized by employing the chemoselective conjugate addition of 3,4-methylenedioxyphenyllithium to **6**, obtained from **5**, and subsequent stereoselective cyclization of **7** to **8** (Scheme 1).<sup>7</sup> Since all stereoisomers are necessary to fully evaluate biological activity of lycorine alkaloids, further study was focused on the stereoselective synthesis of  $\gamma$ -lycorane **3**.<sup>8</sup> We describe herein that the conjugate addition of the aryllithium to a nitroolefin **10** gave highly stereoselectively all *cis*-**11**, which was then converted to **3**.

Since the intramolecular nitro-Michael addition-type cyclization of **7** was sterically controlled by the chirality





Figure 1. Lycoranes **1–3** and lycorine **4**.

**Keywords:** Alkaloid; Synthesis; Nitroolefin; Addition.


\* Corresponding author. Tel.: +81-75-753-4553; fax: +81-75-753-4604;  
e-mail: tomioka@pharm.kyoto-u.ac.jp



Scheme 1. Cyclization and conjugate addition to nitroolefins giving **1**, **2**, and **3**.

at the  $\beta$ -position of a nitro group, cyclization of **5** was expected to give **9**, which is convertible to a nitroolefin **10** (Scheme 1). If the aryllithium addition to **10** takes place *cis* to an acetate moiety, subsequent protonation of a lithium nitronate intermediate takes place from the less hindered face to give all *cis*-**11** bearing the requisite stereochemistry for **3**.


A  $\psi$ -hydroxy- $\omega$ -nitro- $\alpha$ , $\beta$ -enoate **5** was prepared by employing the reported nitro-aldol procedures<sup>9,10</sup> in four steps and 65% overall yield from tetrahydropyran-2-ol.<sup>7</sup> Intramolecular nitro-Michael cyclization of **5** with 2 equiv of cesium fluoride and 0.1 equiv of myristyltrimethylammonium bromide<sup>11</sup> in THF at room temperature for 24 h gave highly stereoselectively a separable diastereomeric mixture of **9** as colorless cubes of mp 89–90 °C in 84% yield and **9a** as a pale yellow oil in 4% yield (Scheme 2).




Scheme 2. Stereoselective nitro-Michael Cyclization of **5** to **9**.

The stereochemistry of **9** was determined by  $^1\text{H}$  NMR (Scheme 2). Coupling constants of methine protons indicate that all substituents on a cyclohexane ring are equatorial in **9**. However, the stereochemistry of **9a** was hard to determine due to the complicated multiplicity of the methine proton attached by a hydroxyl group. PCC oxidation of **9** followed by sodium borohydride reduction of **13** afforded a mixture of **9** in 49% yield and **9a** in 24% yield, confirming **9a** as the epimer of **9** at the carbon attached by a hydroxyl group. Preferred approach of an enoate moiety to a nitronate *anti* to a polarized HO–C bond in **12** is the controlling factor of the highly stereoselective cyclization.<sup>12</sup>

Dehydration of **9** to **10** with methanesulfonyl chloride-triethylamine<sup>13</sup> and trifluoroacetic anhydride-triethylamine,<sup>9</sup> which were effective methods for preparation of aliphatic nitroolefin **6** from **5**, was unsuccessful. Treatment with acetic anhydride-4-*N,N*-dimethylaminopyridine- $\text{Al}_2\text{O}_3$ ,<sup>14</sup> gave an acetylated product without formation of **10**. Fortunately, attempted conversion of an equatorial hydroxyl group to an axial one under the Mitsunobu conditions,<sup>15</sup> diethyl azodicarboxylate-triphenylphosphine-formic acid for 10 min at room temperature, smoothly afforded **10** in an excellently high yield of 94% (Scheme 3).



Scheme 3. Dehydration of **9** under the Mitsunobu conditions and diastereoselective conjugate addition giving **11**.



Scheme 4. Total synthesis of ( $\pm$ )- $\gamma$ -lycorane **3**.

Reaction of **10** with 1.5 equiv of 3,4-methylenedioxyphenyllithium, generated by treating the corresponding bromide with butyllithium at  $-78^\circ\text{C}$  for 15 min in THF, and subsequent protonation with aq ammonium chloride gave an adduct **11**<sup>16</sup> as a sole product in 95% yield with perfect diastereoselectivity (Scheme 3). A pseudo-axially oriented acetate moiety in **14** due to the  $A^{(1,2)}$  strain<sup>17</sup> directed the axial addition of aryllithium to an olefin in **10**. Coordination of a lithium cation to the carbonyl oxygen of the ester **14** may also direct the *cis*-addition of aryllithium reagent. Protonation of the resulting lithium nitronate takes place stereoselectively from the less hindered face of **15** bearing both axial aryl and acetate groups.<sup>18</sup>

Reduction of a nitro group of **11** with zinc powder in 10% aq HCl/ethanol<sup>19</sup> at room temperature for 1 d gave an amine **16** in 99% yield (Scheme 4). Treatment of **16** with sodium methoxide in methanol at room temperature for 3 d afforded a lactam **17** quantitatively, which is the established intermediate<sup>8b</sup> for the synthesis of **3**. Then, the total synthesis of **3** was accomplished in high overall yield according to the reported sequence<sup>8b</sup> through borane–THF reduction and the Pictet–Spengler-type cyclization. Spectroscopic data and the melting point<sup>20</sup> of synthetic ( $\pm$ )- $\gamma$ -lycorane **3** were identical with those reported.<sup>8</sup>

In conclusion, we have succeeded in the stereoselective synthesis of  $\gamma$ -lycorane **3** through a stereoselective intramolecular nitro-Michael cyclization of  $\psi$ -hydroxy- $\omega$ -nitro- $\alpha, \beta$ -enoate **5**, and perfectly diastereoselective *cis*-conjugate addition of aryllithium to a cyclic nitroolefin **10** in high overall yield of 52% from **5** via seven steps. Syntheses of  $\alpha$ -,  $\beta$ -, and  $\gamma$ -lycoranes from the same starting material **5** would be the basis for the further studies toward development of optically active lycorine-based pharmaceuticals.

#### Acknowledgements

This research was partially supported by the 21st Century Center of Excellence Program 'Knowledge Information Infrastructure for Genome Science', a Grant-in-Aid for Scientific Research on Priority Areas (A) 'Exploitation of Multi-Element Cyclic Molecules',

from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and a grant from JSPS.

### References and notes

- (a) Martin, S. F. In *The Alkaloids*; Brossi, A., Ed.; Academic: New York, 1987; Vol. 30, pp 251–376; (b) Grundon, M. F. *Nat. Prod. Rep.* **1989**, *6*, 79–84; (c) Lewis, J. R. *Nat. Prod. Rep.* **1995**, *11*, 339–345; (d) Hoshino, O. In *The Alkaloids*; Cordell, G. A., Ed.; Academic: San Diego, 1998; Vol. 51, pp 323–424.
- Yui, S.; Mikami, M.; Kitahara, M.; Yamazaki, M. *Immunopharmacology* **1998**, *40*, 151–162.
- Review on asymmetric Michael additions to nitroalkenes: Berner, O. M.; Tedeschi, L.; Enders, D. *Eur. J. Org. Chem.* **2002**, 1877–1894.
- External ligand controlled asymmetric reactions: Tomioka, K. *Synthesis* **1990**, 541–549; Recent example: Yamashita, M.; Yamada, K.; Tomioka, K. *J. Am. Chem. Soc.* **2004**, *126*, 1954–1955.
- (a) Takeda, K.; Kotera, K.; Mizukami, S.; Kobayashi, M. *Chem. Pharm. Bull.* **1960**, *8*, 483–486; (b) Kotera, K. *Tetrahedron* **1961**, *12*, 240–247; (c) Kotera, K. *Tetrahedron* **1961**, *12*, 248–261.
- Tsuda, Y.; Isobe, K. *J. Synth. Org. Chem. Jpn.* **1976**, *34*, 625–640.
- Yasuhara, T.; Nishimura, K.; Yamashita, M.; Fukuyama, N.; Yamada, K.; Muraoka, O.; Tomioka, K. *Org. Lett.* **2003**, *5*, 1123–1126.
- Synthesis of **3**: (a) Ueda, N.; Tokuyama, T.; Sakan, T. *Bull. Chem. Soc. Jpn.* **1966**, *39*, 2012–2014; (b) Ganem, B. *Tetrahedron Lett.* **1971**, 4105–4108; (c) Umezawa, B.; Hoshino, O.; Sawaki, S.; Sato, S.; Numao, N. *J. Org. Chem.* **1977**, *42*, 4272–4275; (d) Iida, H.; Yuasa, Y.; Kibayashi, C. *J. Org. Chem.* **1979**, *44*, 1074–1080; (e) Higashiyama, H.; Honda, T.; Otomasu, H.; Kametani, T. *Planta Med.* **1983**, *48*, 268–271; (f) Sugiyama, N.; Nari-miya, M.; Iida, H.; Kikuchi, T. *J. Heterocycl. Chem.* **1988**, *25*, 1455–1457; (g) Baeckvall, J. E.; Anderson, P. G.; Stone, G. B.; Gogoll, A. *J. Org. Chem.* **1991**, *56*, 2988–2993; (h) Pearson, W. H.; Schkeryantz, J. M. *J. Org. Chem.* **1992**, *57*, 6783–6789; (i) Grotjahn, D. B.; Vollhardt, K. P. C. *Synthesis* **1993**, 567–605; (j) Banwell, M. G.; Wu, A. W. *J. Chem. Soc. Perkin Trans. 1* **1994**, 2671–2672; (k) Yoshizaki, H.; Satoh, H.; Sato, T.; Nukui, S.; Shibasaki, M.; Mori, M. *J. Org. Chem.* **1995**, *60*, 2016–2021; (l) Angle, S. R.; Boyce, J. P. *Tetrahedron Lett.* **1995**, *36*, 6185–6188; (m) Ikeda, M.; Ohtani, S.; Sato, T.; Ishibashi, H. *Synthesis* **1998**, 1925–1933; (n) Cossy, J.; Tresnard, L.; Pardo, D. G. *Tetrahedron Lett.* **1999**, *40*, 1125–1128; (o) Cossy, J.; Tresnard, L.; Pardo, D. G. *Eur. J. Org. Chem.* **1999**, 1925–1933; (p) Magnus, P.; Bailey, J. M.; Porter, M. *J. Tetrahedron* **1999**, *55*, 13927–13936; (q) Hoang-Cong, X.; Quiclet-Sire, B.; Zard, S. Z. *Tetrahedron Lett.* **1999**, *40*, 2125–2126; (r) Cassayre, J.; Zart, S. Z. *Synlett* **1999**, 501–503; (s) Banwell, M. G.; Harvey, J. E.; Hockless, D. C. R.; Wu, A. W. *J. Org. Chem.* **2000**, *65*, 4241–4250; (t) Padwa, A.; Brodney, M. A.; Lynch, S. M. *J. Org. Chem.* **2001**, *66*, 1716–1724; (u) Tamura, O.; Matsukida, H.; Toyao, A.; Takeda, Y.; Ishibashi, H. *J. Org. Chem.* **2002**, *67*, 5537–5545; (v) Shao, Z.; Chen, J.; Huang, R.; Wang, C.; Li, L.; Zhang, H. *Synlett* **2003**, 2228–2230.
- Denmark, S. E.; Senanayake, B. W. *J. Org. Chem.* **1993**, *58*, 1835–1858.
- Application of the reported protocols for asymmetric nitro-aldol reaction would give an optically active **5**: (a) Davis, A. P.; Dempsey, K. J. *Tetrahedron: Asymmetry* **1995**, *6*, 2829–2840; (b) Sasai, H.; Tokunaga, T.; Watanabe, S.; Suzuki, T.; Itoh, N.; Shibasaki, M. *J. Org. Chem.* **1995**, *60*, 7388–7389; (c) Sasai, H.; Arai, S.; Tahara, Y.; Shibasaki, M. *J. Org. Chem.* **1995**, *60*, 6656–6657; (d) Magnus, P.; Pye, P. *Chem. Commun.* **1995**, 1933–1934; (e) Iseki, K.; Oishi, S.; Sasai, H.; Shibasaki, M. *Tetrahedron Lett.* **1996**, *37*, 9081–9084; (f) Hanessian, S.; Devasthale, P. V. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 2201–2206; (g) Oshida, J.; Okamoto, M.; Azuma, S.; Tanaka, T. *Tetrahedron: Asymmetry* **1997**, *8*, 2579–2584; (h) Takaoka, E.; Yoshikawa, N.; Yamada, Y. M. A.; Sasai, H.; Shibasaki, M. *Heterocycles* **1997**, *46*, 157–163; (i) Menzel, A.; Ohrlein, R.; Griesser, H.; Wehner, V.; Jager, V. *Synthesis* **1999**, 1691–1702; (j) Knudsen, K. R.; Risgaard, T.; Nishiwaki, N.; Gothelf, K. V.; Jorgensen, K. A. *J. Am. Chem. Soc.* **2001**, *123*, 5843–5844; (k) Davis, A. V.; Driffield, M.; Smith, D. K. *Org. Lett.* **2001**, *3*, 3075–3078; (l) Yukihira, M.; Matsumoto, K. *Angew. Chem., Int. Ed.* **2002**, *41*, 1031–1033; (m) Tian, J.; Yamagiwa, N.; Matsunaga, S.; Shibasaki, M. *Angew. Chem., Int. Ed.* **2002**, *41*, 3636–3638; (n) Sasai, H.; Watanabe, S.; Suzuki, T.; Shibasaki, M. *Org. Synth.* **2002**, *78*, 14–22; (o) Ooi, T.; Doda, K.; Maruoka, K. *J. Am. Chem. Soc.* **2003**, *125*, 2054–2055.
- Corey, E. J.; Zhang, F.-Y. *Org. Lett.* **2000**, *2*, 4257–4259.
- Although the possibility of thermodynamic control is not excluded, attempted epimerization of a nitro group (NaOMe in MeOH) recovered **11**.
- Melton, J.; McMurry, J. E. *J. Org. Chem.* **1975**, *40*, 2138–2139.
- Ballini, R.; Palestini, C. *Tetrahedron Lett.* **1994**, *35*, 5731–5734.
- (a) Mitsunobu, O. *Synthesis* **1981**, 1–28; (b) Prange, T.; Rodríguez, M. S.; Suárez, E. *J. Org. Chem.* **2003**, *68*, 4422–4431.
- Coupling constants (*J*) of a methine proton (CHNO<sub>2</sub>) at  $\delta$  5.01 are 4.0 and 4.1 Hz, indicating all-*cis* arrangement of three substituents in **11**.
- (a) Johnson, F. *Chem. Rev.* **1968**, *68*, 375–413; (b) Tomioka, K. *J. Synth. Org. Chem. Jpn.* **1993**, *51*, 1116–1123.
- Castello, A.; Jaime, C.; Marquet, J.; Moreno-Manas, M. *Tetrahedron* **1985**, *41*, 3791–3802.
- Michaelides, M. R.; Hong, Y.; DiDomenico, S., Jr.; Bayburt, E. K.; Asin, K. E.; Britton, D. R.; Lin, C. W.; Shiosaki, K. *J. Med. Chem.* **1997**, *40*, 1585–1599.
- Melting point of synthetic ( $\pm$ )-**3**: 104–105 °C (105–106 °C).<sup>8c</sup>